T315I BCR-ABL Mutation Analysis (Quantitative)
For monitoring of the levels of the Thr to Ile mutation at codon 315 (T315I) of the BCR-ABL kinase seen in CML patients who have developed resistance to imatinib or other kinase inhibitors.
PCR-based pyrosequencing of RNA is performed to examine mutational status of codons 315 of the BCR-ABL fusion transcript. The ratio of mutated/unmutated PCR product at codon 315 is reported.
CML clone must comprise at least 5% of the cells in the sample for accurate assessment. Levels are quantitative with approximately 5-10% variability.
Five to seven days
- 10 mls peripheral blood (PB) in purple top tube (EDTA Vacutainer), sent on wet ice
- 2-5 ml of bone marrow aspirate (BM), sent on wet ice
- 10 µg of purified RNA, sent on dry ice
- 5-10 µg of cDNA, sent on dry ice
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.